Cencora, Inc. (NYSE:COR) Shares Acquired by City State Bank

City State Bank lifted its position in shares of Cencora, Inc. (NYSE:COR) by 19.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 618 shares of the company’s stock after purchasing an additional 100 shares during the period. City State Bank’s holdings in Cencora were worth $139,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in COR. LPL Financial LLC increased its holdings in shares of Cencora by 6.3% during the 2nd quarter. LPL Financial LLC now owns 164,327 shares of the company’s stock worth $37,023,000 after buying an additional 9,697 shares during the last quarter. BOKF NA increased its holdings in shares of Cencora by 106.0% during the 2nd quarter. BOKF NA now owns 2,200 shares of the company’s stock worth $496,000 after buying an additional 1,132 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Cencora by 6.4% during the 2nd quarter. Parallel Advisors LLC now owns 4,961 shares of the company’s stock worth $1,118,000 after buying an additional 299 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Cencora by 2.2% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 28,452 shares of the company’s stock worth $6,410,000 after buying an additional 616 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Cencora by 4.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 560,450 shares of the company’s stock worth $126,269,000 after buying an additional 22,735 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Evercore ISI increased their price target on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Wells Fargo & Company decreased their target price on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research report on Friday, December 13th. Barclays boosted their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. UBS Group increased their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Mizuho assumed coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $275.60.

Cencora Stock Down 0.0 %

COR stock opened at $236.10 on Tuesday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $253.27. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The company has a market capitalization of $45.63 billion, a P/E ratio of 31.44, a PEG ratio of 1.54 and a beta of 0.49. The firm has a 50 day simple moving average of $237.82 and a 200-day simple moving average of $233.54.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.93%. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the sale, the chairman now directly owns 306,752 shares of the company’s stock, valued at $74,283,064.32. The trade was a 6.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 94,696 shares of company stock valued at $22,862,734. 15.80% of the stock is currently owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.